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1. Introduction 
Despite appropriate anticoagulant therapy, at least 1 of every 2-3 patients with deep-vein 
thrombosis (DVT) of the lower extremities will develop post-thrombotic sequelae. These vary 
from minor signs (i.e., stasis pigmentation, venous ectasia, slight pain and swelling) to severe 
manifestations such as chronic pain, intractable edema and leg ulcers (1). The established post-
thrombotic syndrome (PTS) remains a significant cause of chronic illness, with considerable 
socio-economic consequences for both the patient and the health care services (2,3). 
The precise incidence of the PTS following confirmed venous thrombosis is still 
controversial, as the rate of post-thrombotic sequelae reported in published studies has 
varied between 20% and 100%. In earlier studies, a surprisingly high rate of severe PTS 
complications was reported (50 to 100% of the patients within 4 to 10 years after the 
qualifying thrombotic episode) (4-6). This rate sharply decreased in studies performed in the 
last 25 years (7-39), which could be due to improved diagnostic and therapeutic approaches 
to patients with DVT. However, owing to large differences among studies in terms of study 
design, definition of PTS, sample size, length of follow-up, and use of compression elastic 
stockings, the reported incidence of both overall and severe PTS still shows considerable 
variability. In the absence of elastic stockings, PTS is expected to develop in approximately 
50% of patients suffering an episode of DVT, and is severe in one fifth of patients (1). Of 
interest, PTS can develop, although to a lower extent, also after an asymptomatic episode of 
postoperative DVT (40,41). 
According to the results of the most recent studies, most patients who develop post-
thrombotic manifestations become symptomatic within two years from the acute episode of 
DVT (1,18-20,29-32,35-37,39). These findings challenge the general view that the PTS 
requires many years to become manifest.  
2. Clinical diagnosis and objective diagnostic testing 
2.1 Clinical diagnosis and scoring systems 
The post-thrombotic syndrome is characterized by aching pain on standing, dependent 
edema, and the frequent development of brawny, tender induration of the subcutaneous 
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tissues of the medial lower limb, a condition that has been termed "lipodermatosclerosis". 
Pruritus and eczematous skin changes are frequently present, and a proportion of patients 
develops secondary superficial varicose veins as the syndrome evolves. Ulceration, often 
precipitated by minor trauma, arises in a considerable number of patients and is 
characteristically chronic and indolent with a high recurrence rate, once healing has been 
achieved. Uncommonly, patients with persistent obstruction may experience venous 
claudication, a bursting pain in the leg during exercise, which, in some respects, mimics 
arterial claudication (42). 
The clinical picture of the PTS is non-specific, as clinical conditions other than DVT may 
result in a similar set of symptoms and signs in the lower extremity, including superficial 
venous insufficiency, increased body mass index, and trauma (43-45).  
The diagnosis of the PTS is made based on the development of the above mentioned clinical 
manifestations in patients with a history of DVT, irrespective of the presence of venous 
abnormalities as shown by invasive or non-invasive diagnostic procedures. In the absence of 
characteristic signs and symptoms, the demonstration of venous abnormalities (such as 
venous reflux, persistent venous obstruction, or both) does not, in itself, allow a patient with 
a history of DVT to be defined as having PTS.  
Subjective Symptoms Objective Signs 
Heaviness Pretibial edema 
Pain nduration of the skin 
Cramps Hyperpigmentation 
Pruritus New venous ectasia 
Paresthesia 
Redness 
Pain during calf compression 
Ulceration of the skin 
*Each sign or symptom is graded with a score between 0 and 3. The presence of ulcer is only noted. 
PTS is classified as mild if the score is 5-9, moderate if the score is 10-14, and severe if the score is ≥ 15 or 
a venous ulcer is present. 
Table 1. Villalta scale for the assessment of the PTS 
Although the clinical picture of the PTS is classical, there is large variation among published 
studies as to its clinical classification. Among the suggested scoring systems, the Villalta 
scale and the CEAP classification are the most widely adopted (46). The former, based on 
clinical findings alone (Table 1), has high interobserver agreement (47,48), and good ability 
to discriminate patients with versus those without PTS and patients with mild versus those 
with severe PTS (1,47,49). In addition, this scale correlates well with the patient's perception 
of the interference of leg complaints with daily life (31,47,49). The Villalta scale has recently 
been recommended as a standard to define PTS for use in clinical investigations by the 
Scientific and Standardization Committee of the International Society on Thrombosis and 
Haemostasis (50). The latter, known as CEAP (Clinical, Etiologic, Anatomic, 
Pathophysiologic) classification, was developed as a result of the cooperative work of a 
panel of experts in the field of vascular disease, and combines clinical and objective findings 
into a sophisticated scoring system (Table 2) (51). 
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Clinical signs Class 0 No visible or palpable signs of venous 
disease 
Class 1 Telangiectasia or reticular veins 
Class 2 Varicose veins 
Class 3 Edema 
Class 4 Skin changes ascribed to venous disease 
Class 5 Skin changes as described above with 
healed ulceration 
Class 6 Leg ulceration, skin changes as defined 
above 
Etiologic classificatio Congenital, primary, secondary 
Anatomic distribution Superficial, deep, or perforator, alone or in combination 
Pathophysiologic 
dysfunction 
Reflux or obstruction, alone or in combination 
Table 2. CEAP (clinical, etiologic, anatomic, pathophysiologic) classification of the PTS 
2.2 Objective diagnostic testing 
If a patient with a history of a previous (documented or highly suspected) DVT develops 
symptoms and signs compatible with PTS there is no need for further investigation. As the 
clinical picture may be non-specific (43-45), the need for objective confirmation arises in 
patients with leg complaints but without a likely or objectively proven previous DVT. 
Ascending phlebography is potentially useful to detect a previous DVT. Suggestive findings 
include narrowing or occlusion of the deep veins, contrast dye opacification of fewer veins 
(than normal) or perfusion of superficial or deep collateral veins. Recanalized veins show 
irregular margins, bizarre-appearing or multi-channeled lumen with webs, and usually 
have reduced caliber due to fibrotic thickening of their walls. Such veins may subsequently 
become dilated, probably because of loss of their elastic tissue (52). Despite the predictive 
value of these venographic patterns in patients with possible PTS, the invasive nature and 
cost of plebography makes such an approach inapplicable to most patients with a history of 
clinically suspected DVT. 
We have shown that the combination of standardized clinical evaluation with compression 
ultrasonography and continuous-wave Doppler analysis can reliably diagnose or exclude a 
prior proximal-vein thrombosis in almost 90% of patients with a suggestive history (53). 
Compression ultrasonography should be performed first, checking the popliteal and the 
common femoral vein for compressibility. If either or both veins are incompressible, then a 
definite diagnosis of previous (proximal) DVT is made. Patients with normal ultrasound test 
results are interviewed and examined according to a standardized form (Table 1), and 
subsequently undergo continuous-wave Doppler analysis to test valve function, both in the 
common femoral and in the popliteal vein. The finding of both a popliteal reflux and/or of a 
clinical score > 8 is highly specific for the adjudication of a prior DVT in patients with a 
normal ultrasound test result. If ultrasound testing is normal, deep venous reflux is absent, 
and the clinical score is < 8, then previous proximal DVT is virtually excluded (53). The 
widespread availability of Duplex scanning renders our approach even more rapid and 
precise, as it permits venous flow sampling during direct visualization of the vessels.  
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Besides the demonstration of previous episodes of DVT, either invasive or non-invasive 
methods can be employed to document and quantify the presence of obstruction, reflux, or 
both, that are considered the major determinants of the PTS.  
3. Pathophysiology of PTS development 
It is generally believed that the PTS develops as a result of the combination of venous 
hypertension, due to persistent outflow obstruction and/or valvular incompetence, with 
abnormal microvasculature or lymphatic function. Long-standing venous hypertension in the 
deep-vein system ultimately leads to the onset of valve incompetence at the level of a constant 
series of perforating veins located in the medial ankle area. This allows the direct transmission 
of the high deep-venous pressures (especially during walking) to the venous end of 
subcutaneous capillaries, resulting in increased endothelial permeability. The escape of large 
molecules into the interstitial tissue may, in turn, explain the typical pattern of edema, 
hyperpigmentation and even ulcer formation (42,44,45). A few authors speculate that 
increased venous pressure with standing or walking causes a reduction in capillary flow rate, 
resulting in trapping of white blood cells in the leg and the subsequent release of free radical 
and proteolytic enzymes ultimately responsible for the venous ulceration (54,55). 
The presence of reflux in the proximal veins is reputed to be crucial for the development of 
the PTS, and so is the persistence of venous obstruction, alone or in combination with 
venous reflux (15,35,56-61). However, this is an area of considerable uncertainty. Recently, 
we assessed the role of residual vein thrombosis and popliteal valve incompetence for the 
development of the PTS, as measured with the Villalta scale, in 180 consecutive patients 
who were followed for at least three years after an episode of acute proximal DVT (62). In 
the first six months following the thrombotic episode, venous abnormalities were detected 
in 104 patients (60%). The PTS developed in 18 of the 76 patients (24%) without vein 
abnormalities, and in 49 of the 104 (47%) with at least one abnormality: in 25 of the 52 (48%) 
with residual vein thrombosis alone, in 9 of the 24 (37.5%) with popliteal valve 
incompetence alone, and in 15 of the 28 (54%) with both abnormalities. The relative risk of 
the PTS was 1.0 (95% CI, 0.5 to 2.2) in patients with popliteal valve incompetence alone; 1.4 
(0.9 to 2.3) in patients with transpopliteal reflux alone or combined with persistent venous 
obstruction; 1.6 (1.0 to 2.4) in patients with residual vein thrombosis alone; and 1.7 (1.2 to 
2.3) in patients with persistent venous obstruction alone or combined with popliteal valve 
incompetence. 
Roumen-Klappe and coworkers assessed the role of residual thrombosis, reflux and venous 
outflow resistance in 93 patients with proximal and distal DVT, followed for 6 years; the 
incidence of the PTS was 49% after 1 year, 55% after 2 years, without further increase up to 6 
years. While the presence of reflux had only moderate predictive value, a strong increase in 
the predictive value was achieved by combining measures of residual thrombus, assessed by 
a thrombosis score, and venous outflow resistance, at three months (32). On the basis of 
these findings, a lack of recanalization within the first six months after the thrombotic 
episode appears to be an important predictor of PTS, while the development of 
transpopliteal venous reflux is not. However, incompetence of the popliteal valve increases 
the risk of the PTS when combined with residual vein thrombosis (32,62).  
In a recent report, increased levels of inflammatory cytokines or adhesion molecules such as 
IL-6 and ICAM-1 were linked with the subsequent development of PTS (63). This suggests 
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that inflammation at the time of, or consequent to the episode of acute DVT may play a role 
in the pathophysiology of PTS, a hypothesis that is being further explored in a large 
prospective study (64). 
4. Predictors of PTS development 
Among parameters that have been found to be associated with an increased risk of the PTS 
are proximal DVT (33,38,39,60), previous ipsilateral DVT (14,16,18,28,29,33,39), older age 
(29,65), obesity (38,39,65-67), and varicose veins (38). In one investigation the male gender 
was a predictor of the PTS (33), while in others the opposite was seen (38,39). Finally, 
whether the carriage of factor V Leiden or the prothrombin mutation are predictors of a 
lower risk or reduced severity of the PTS is controversial, as there are data in favor (31) and 
against (38,39) this association. 
In order to determine the frequency, time course, and predictors of the PTS after acute DVT, 
we followed 387 patients for up to two years after an episode of acute symptomatic DVT 
(39). With the use of the Villalta score, greater postthrombotic severity category at the 1-
month visit strongly predicted higher mean postthrombotic scores throughout 24 months of 
follow-up (1.97, 5.03, and 7.00 increase in Villalta score for mild, moderate, and severe 1-
month severity categories, respectively, vs. none). Additional predictors of higher scores 
over time were venous thrombosis of the common femoral or iliac vein (2.23 increase in 
score vs. distal venous thrombosis), higher body mass index (0.14 increase in score per 
kg/m2), previous ipsilateral venous thrombosis (1.78 increase in score), older age (0.30 
increase in score per 10-year age increase), and female sex (0.79 increase in score). 
Accordingly, appropriate strategies aimed at reducing the risk of recurrent DVT, and 
reducing the body weight in obese patients have the potential to help prevent late post-
thrombotic sequelae. 
Proximal DVT is associated with a higher frequency and more severe PTS than distal DVT. 
In the abovementioned study, patients with more extensive proximal (femoral or iliac vein) 
DVT had significantly worse PTS scores at all visits (adjusted average increase of > 2 points 
on the Villalta scale) than those with distal or popliteal vein DVT (39). Similarly, in another 
recent prospective study, proximal DVT was found to be associated with a 2-fold increased 
risk of PTS compared with distal DVT (33). As the rates of PTS in the control arms of trials of 
compression stockings to prevent PTS in patients with proximal DVT ranged from 40-50%, 
the rate of PTS after distal DVT is likely to be in the range of 20-25%, however in one study, 
symptoms of PTS after distal DVT were relatively mild (23).  
Finally, an insufficient quality of oral anticoagulant therapy following the acute thrombotic 
episode has been found to be associated with an increased risk of the PTS (28,65). 
Accordingly, appropriate attention to the monitoring of oral anticoagulant therapy 
following the initial thrombotic episode, in terms of both adequate intensity and duration, 
has the potential to help prevent late post-thrombotic sequelae.  
5. Treatment of the PTS 
Once established, PTS, especially when complicated by leg ulceration, is a significant cause 
of disability with a considerable economic burden for both patients and the health care 
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system (1,2). The management of this condition is demanding and oftentimes frustrating. 
Several treatment strategies, both conservative and surgical, have been tested, especially 
aimed at ulcer healing. 
5.1 Conservative treatment 
Compression therapy, either obtained with short stretch bandages, adhesive bandages, 
multiple layer bandages (with orthopedic wool plus compressive layers), stockings or zinc 
bandages, and frequent leg elevation are the cornerstones of the conservative management 
of venous ulcer (67). Irrespective of the choice, effective compression therapy is obtained 
with implements exerting a 35 to 40 mm Hg pressure at the ankle (68). Greater benefits 
(higher and faster healing rates, and low recurrence rates) are to be expected if compliance 
with compression therapy is monitored through ambulatory care programs, and if patients 
are encouraged to take regular exercise and to elevate the extremities while resting (69-71). 
According to the results of a survey conducted among Canadian physicians and patients, 
most patients with DVT reported being willing to comply with elastic stockings therapy and 
found them useful (72), although their use neither improves leg symptoms and signs during 
exercise nor increases exercise capacity (73). 
In a randomized clinical trial conducted in a small number of patients with severe PTS, the 
adoption of cycles of intermittent pneumatic compression was found to reduce both 
intractable edema and leg swelling (74). In another randomized trial, a novel lower-limb 
venous-return assist device (VENOPTS) was found to considerably improve the clinical 
manifestations of severe PTS both alone and in combination with compression stockings 
(75). Finally, in a recent randomized clinical trial patients with PTS were found to benefit 
from an exercise training (a six-month trainer-supervised program that included aerobic, leg 
stretching and strengthening components) to a greater extent than those who had 
conventional treatment alone both in terms of severity of complaints and improvement in 
quality of life (76). 
In addition to compressive therapy, a number of active compounds have been evaluated in a 
series of small randomized trials for the healing of venous ulcers. Among these 
oxpentifylline (77), aspirin (78), intravenous prostaglandin E1 (79), sulphydril-containing 
agents (DL-cysteine or DL-methionine) (80), radical scavengers (allopurinol or dimethyl 
sulfoxide) (81), and sulodexide (82) significantly improved the ulcer-healing rate. 
With regards to other manifestations of the PTS, two small randomized trials demonstrated 
some beneficial effect of an anabolic steroid (stanozolol) plus elastic stockings on 
lipodermatosclerosis (83), and that of 0-(-hydroxyethyl)-rutosides on edema and several 
milder PTS symptoms (84), respectively.  
In a recent clinical trial, we evaluated the efficacy of elastic compression stockings, 
hydroxyethylrutosides or both for the treatment of PTS (85). In 120 consecutive patients 
with PTS who were randomized to receive below-knee elastic stockings (30-40 mm Hg at the 
ankle), oral administration of hydroxyethylrutosides (1000 mg b.i.d.) or both for one year, an 
improvement of PTS manifestations was observed in similar proportions of patients in each 
study group. According to these results, elastic stockings and hydroxyethylrutosides seem 
equally effective in patients with the PTS. The combination of the two remedies does not 
seem to improve the results obtained by each strategy alone. 
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5.2 Surgical treatment 
Surgery is often advocated when severe clinical manifestations (e.g. ulcer) cannot be managed 
by conservative treatment: various strategies are available, among whom subfascial perforator 
ligation and valvuloplasty appear to be the most promising (86). A more recent trial on 
subfascial endoscopic perforator surgery plus correction of superficial venous reflux indicates 
that, although effective in improving symptoms and ulcer healing in patients with primary 
venous insufficiency, this procedure is not as effective in patients with PTS (87). Similarly, 
deep (femoral-popliteal) valve reconstruction surgery performed after unsuccessful 
endoscopic perforator surgery, and correction of superficial venous reflux, yields significantly 
better results in patients with primary venous insufficiency than in patients with PTS (88). 
6. Prevention of the PTS 
6.1 Initial treatment of DVT with thrombolytic drugs 
Thrombolysis has been traditionally advocated as an alternative strategy to heparins for the 
initial treatment of DVT, based on the assumption that early vein recanalization will result 
in a more favorable long-term outcome. This assumption is in agreement with the findings 
from several recent studies, which have identified that proximal location of the initial 
thrombosis is among the strongest predictors of PTS development (33,38,60), especially 
when the thrombus involves the ilio-femoral segments (39). Consistent with this assumption 
is the demonstration that post-thrombotic complications develop predominantly in those 
patients in whom the initial complaints tend to persist (39). Both the intravenous infusion of 
thrombolytic drugs and the use of catheter-directed thrombolysis are likely to result in a 
higher frequency of early vein patency as compared to heparin (89-92). However, whether 
these therapeutic approaches improve the long-term patients’ outcome as well is 
controversial, as there is data in favour (93-96) and against (97,98) this possibility. In 
addition, the use of either intravenous or catheter-directed thrombolysis is associated with a 
higher risk of complications compared with treatment with anticoagulants alone (90,100). 
Thus, the routine use of early thrombolytic therapy for the prevention of long-term sequelae 
of DVT does not seem to be currently justified, but is the subject of ongoing multicenter 
randomized trials (100).  
6.2 Compression bandaging in the acute phase of DVT 
In order to assess the influence of immediate multilayer compression bandages before 
application of elastic stockings in the acute phase of DVT on development of the PTS, 69 
patients with acute symptomatic DVT were recently randomized to immediate bandaging 
or no bandaging (36). While bandaging resulted in a considerable improvement of clinical 
symptoms and decrease of leg circumference in the first week of treatment, no difference in 
the development of late sequelae was observed between the two groups after one year. 
Thus, the early application of bandages in patients with DVT is unlikely to improve the 
long-term patients’ outcome. 
6.3 Elastic compression stockings 
Elastic compression stockings have long been utilized for the prevention of the PTS in 
patients with acute DVT (72). However, their efficacy had not been systematically 
investigated until a few years ago.  
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In 1997, the results of a prospective randomized Dutch study on the prevention of the PTS 
became available (19). In this trial, 194 consecutive patients with confirmed proximal DVT 
were allocated to wear or to not wear elastic compression stockings. A predefined scoring 
system was used to classify patients into three categories: no, mild-to-moderate, and severe 
PTS. After a median follow-up of 76 months, mild-to-moderate PTS occurred in 19 (20%) 
and severe PTS in 11 (11.5%) of the 96 patients with stockings, while these occurred in 46 
(47%) and 23 (23.5%) of the 98 patients without stockings, respectively (p<0.001).  
These results were recently confirmed by a prospective, controlled, randomized study 
performed in Italy (29), in which 180 consecutive patients with a first episode of 
symptomatic proximal DVT who were planned to receive conventional anticoagulant 
treatment were randomized to wear or to not wear below-knee compression (30-40 mm Hg 
at the ankle) elastic stockings for two years. Follow-up was performed for up to 5 years. 
Post-thrombotic sequelae, as assessed with the Villalta scale, developed in 44 of the 90 
control patients (severe in 10), and in 23 of the 90 patients who were randomized to wear 
elastic stockings (severe in 3). After adjustment for baseline characteristics, the hazard ratio 
for the PTS in the stockings group as compared to the control group was 0.5 (0.3 to 0.8). A 
large, multicenter randomized trial is currently underway in North America to compare 
active versus placebo stockings to prevent PTS after proximal DVT (64). 
Although the results of an investigation conducted in Canada (101) were not consistent with 
those of the above described studies (19,29,37), a recent meta-analytic review emphasized the 
role of graduated compression stockings for preventing long-term post-thrombotic sequelae 
(102). Accordingly, the latest edition of the American College of Chest Physicians has recently 
recommended elastic stockings beside conventional anticoagulation in all patients with acute 
symptomatic DVT, if feasible (99). While the effectiveness of compression stockings to prevent 
PTS after distal DVT has not been studied, it would be reasonable to offer compression 
stockings to patients with severe symptoms related to distal DVT. 
Knee-length and thigh-length compression elastic stockings have similar physiologic effects 
in decreasing venous stasis of the lower limb, but the former are easier to apply and are 
more comfortable (103). A recent systematic review of knee versus thigh length graduated 
compression stockings for the prevention of DVT concluded that knee length were as 
effective as thigh length stockings and offer advantages in terms of patient compliance and 
cost (104). In order to directly compare the effectiveness and tolerability of below-knee 
versus thigh length stockings at the time of acute DVT to prevent PTS a randomized clinical 
trial has been conducted at our institution, whose results will be available soon (105). 
The optimal duration of the treatment with elastic stockings has received little attention. In a 
recent trial, 169 patients with a first or recurrent proximal DVT who had received 6 months 
of standard compression treatment were randomized to wear or to not wear graduated 
elastic stockings for an additional 18 months (37). Overall, after 6 years of follow-up, 
prolongation of compression therapy failed to confer an additional advantage - according to 
the CEAP classification – over and above the initial 6-month period. However, when the 
analysis was confined to women, there was a statistically significant advantage to 
prolonging treatment with compression stockings. In a prospective cohort management 
study, the discontinuation of elastic stockings in patients free from PTS complaints who had 
been offered at least six months of compression therapy did not increase the rate of PTS 
development over patients in whom stockings had been used for at least two years 
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irrespective of the presence of post-thrombotic manifestations (106). Further studies are 
needed to show whether compression therapy is or is not indicated in asymptomatic 
patients who have completed an initial 6-month period. 
To our knowledge, there are no studies that have compared different compression strengths 
of stockings to prevent PTS. It would be worth studying the effectiveness of lighter 
compression (20-30 mm Hg) stockings as they are easier to apply, especially for elderly 
patients, than 30-40 mm Hg stockings. Of note, in a study of stockings to prevent recurrent 
venous ulcer, there was no difference in effectiveness between class 2 and class 3 stockings 
(107). 
Interestingly enough, immediate mobilization in patients with acute DVT may reduce the 
rate of PTS development, provided that patients are provided with adequate compression 
therapy (108).  
6.4 The potential of new anticoagulant drugs 
An insufficient quality of oral anticoagulant therapy following the acute thrombotic episode 
has been found to be associated with an increased risk of the PTS (28,65). Conversely, the 
long-term use of LMWH has been found to reduce the PTS rate in comparison with vitamin 
K antagonists (35,109). We cannot exclude, therefore, the potential of a few emerging 
antithrombotic compounds (such as dabigatran etexilate and rivaroxaban), which can be 
administered orally in fixed daily dosage and have been found to be at least as effective and 
safe as conventional anticoagulation for the initial and long-term treatment of DVT 
(110,111), for further reducing the incidence and the severity of the PTS. 
7. Prognosis 
It is commonly believed that patients with established PTS have a poor prognosis, and that 
the majority will have sustained disability. In recent years, a few reports have suggested that 
prognosis of the PTS might not be as poor as previously reported (69-71). Indeed, when 
provided with elastic compression stockings and regularly supervised, more than 50% of 
patients either remain stable or improve during long-term follow-up, irrespective of the 
initial degree of PTS (69-71). Clinical presentation helps predict the prognosis, as the 
outcome of patients who have initially severe manifestations appears to be more favorable 
than that of patients whose symptoms progressively deteriorate over time (71). However, at 
present there is no way to reliably predict the course of PTS in individual patients. 
8. Conclusion 
PTS is a frequent, burdensome and costly complication of DVT. Currently, there are few 
effective treatments for PTS. Until such treatments are identified, prevention of PTS will 
have the greatest impact on reducing the overall burden of PTS on patients and society. 
Preventing DVT recurrence is likely to reduce the risk of PTS. Daily use of graduated ECS 
after DVT appears to reduce the risk of PTS. As of yet, there is no established role for 
thrombolysis in preventing PTS, but trials are underway to address this important question. 
Research is also underway to identify biologic markers that may predict the risk of PTS in 
individual patients. Finally, a few emerging antithrombotic compounds may have the 
potential to reduce the risk of PTS, however this requires further study. 
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